Please assess the completion status of the following clinical trial:

Trial Title: A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a male or female between the ages of 2 and 80 years (inclusive), is able to provide informed consent or assent, and agrees to use contraceptive methods during the study (unless documented as biologically or surgically sterile or has not reached reproductive age).~* Subject has documented history of hypoplasminogenemia and has plasminogen activity level ≤ 45%.~* Subject had a documented history of lesions and symptoms consistent with a diagnosis of congenital plasminogen deficiency.~* Subject has documented vaccination to hepatitis A virus (HAV) and hepatitis B virus (HBV), or has received the first dose of HAV and HBV vaccine prior to the first dose of IMP and is scheduled to receive the second vaccine dose.~Exclusion Criteria:~* Subject has uncontrolled hypertension; clinical or laboratory evidence of an intercurrent infection; a malignancy within 3 years, except for basal or squamous cell skin cancer; a psychiatric disorder; chronic or acute clinically significant inter-current illness; or evidence of renal and hepatic dysfunction.~* Subject is pregnant or lactating~* Subject has a history of anaphylactic reactions to blood or blood products that may interfere with participation in study in the opinion of the investigator.~* Subject is a previous organ transplant recipient; has received exogenous plasminogen within 2 weeks of the screening; has a history of anaphylactic reactions to blood or blood products; or has received another IRB-approved interventional clinical trial of a drug, biologic, or device within 30 days before the first dose of the IMP.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 6.6 mg/kg Plasminogen (Human) Intravenous (Type: EXPERIMENTAL): 6.6 mg/kg Plasminogen (Human) Intravenous given every 2 to 4 days by a 10- to 30-minute intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).